<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Pharmacokinet</journal-id><journal-id journal-id-type="iso-abbrev">Clin Pharmacokinet</journal-id><journal-title-group><journal-title>Clinical Pharmacokinetics</journal-title></journal-title-group><issn pub-type="ppub">0312-5963</issn><issn pub-type="epub">1179-1926</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28028767</article-id><article-id pub-id-type="pmc">5247543</article-id><article-id pub-id-type="publisher-id">493</article-id><article-id pub-id-type="doi">10.1007/s40262-016-0493-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Authors&#x02019; Reply to Kamel et al.: &#x0201c;Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study&#x0201d;</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4582-3679</contrib-id><name><surname>Glund</surname><given-names>Stephan</given-names></name><address><phone>+49 (7351) 54-93817</phone><email>stephan.glund@boehringer-ingelheim.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Reilly</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>van Ryn</surname><given-names>Joanne</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Stangier</surname><given-names>Joachim</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 7500</institution-id><institution-id institution-id-type="GRID">grid.420061.1</institution-id><institution>Translational Medicine and Clinical Pharmacology, </institution><institution>Boehringer Ingelheim Pharma GmbH &#x00026; Co. KG, </institution></institution-wrap>Birkendorfer Stra&#x000df;e 65, 88397 Biberach an der Riss, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1312 9717</institution-id><institution-id institution-id-type="GRID">grid.418412.a</institution-id><institution/><institution>Boehringer Ingelheim Pharmaceuticals, Inc., </institution></institution-wrap>Ridgefield, CT USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 7500</institution-id><institution-id institution-id-type="GRID">grid.420061.1</institution-id><institution/><institution>Boehringer Ingelheim Pharma GmbH &#x00026; Co. KG, </institution></institution-wrap>Biberach an der Riss, Germany </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>56</volume><issue>2</issue><fpage>209</fpage><lpage>210</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing Switzerland 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>We thank Dr. Kamel and colleagues for their valuable comments [<xref ref-type="bibr" rid="CR1">1</xref>] and would like to provide the following response to the questions raised.</p><p>The unbound dabigatran concentration reflects the level of active dabigatran in the blood. Administration of idarucizumab 5&#x000a0;g to volunteers of various age groups and with different degrees of renal impairment reduced unbound dabigatran concentrations to below the lower limit of quantitation (LLOQ) (1&#x000a0;ng/mL). Approximately 12&#x02013;16&#x000a0;h post-idarucizumab administration, an increase in the concentrations of unbound dabigatran above the LLOQ was noted. Importantly, the underlying detection methodology is highly sensitive and, over the entire observation period, levels did not increase above the threshold for pharmacological activity. Consequently, coagulation time measurements also did not increase above their respective upper limits of normal, as illustrated for activated partial thromboplastin time in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Activated partial thromboplastin time (s) [mean (standard deviation)] values obtained 24&#x02013;120&#x000a0;h after administration of idarucizumab 5&#x000a0;g in volunteers with mild or moderate renal impairment, pre-treated with dabigatran etexilate 150&#x000a0;mg twice daily; upper limit of normal&#x000a0;=&#x000a0;39.8&#x000a0;s</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Group</th><th align="left">24&#x000a0;h</th><th align="left">48&#x000a0;h</th><th align="left">72&#x000a0;h</th><th align="left">96&#x000a0;h</th><th align="left">120&#x000a0;h</th></tr></thead><tbody><tr><td align="left">Mild RI</td><td align="left">32.7 (0.85)</td><td align="left">33.0 (0.96)</td><td align="left">30.9 (1.58)</td><td align="left">29.6 (3.02)</td><td align="left">30.7 (2.09)</td></tr><tr><td align="left">Moderate RI</td><td align="left">33.3 (5.64)</td><td align="left">32.7 (4.60)</td><td align="left">31.1 (2.21)</td><td align="left">30.8 (2.22)</td><td align="left">31.3 (2.75)</td></tr></tbody></table><table-wrap-foot><p>
<italic>RI</italic> renal impairment</p></table-wrap-foot></table-wrap>
</p><p>A 5&#x000a0;g dose of idarucizumab completely neutralizes dabigatran anticoagulation in almost all patients, as demonstrated by coagulation time measurements in dabigatran-treated patients receiving idarucizumab as emergency treatment [<xref ref-type="bibr" rid="CR2">2</xref>]. Coagulation time measurements are frequently applied as routine measures in clinical emergency settings, and the results can provide important information supporting rational treatment decisions. In RE-VERSE&#x000a0;AD (REVERSal Effects of idarucizumab in patients on Active Dabigatran), patients&#x02019; coagulation times were determined up to 24&#x000a0;h after idarucizumab administration [<xref ref-type="bibr" rid="CR2">2</xref>]. In this timeframe most clinical emergencies are expected to resolve. A re-occurrence of dabigatran anticoagulation was noted in some patients, mostly 12&#x02013;24&#x000a0;h after idarucizumab administration [<xref ref-type="bibr" rid="CR2">2</xref>]. Importantly, almost none of these patients were bleeding, suggesting that for these patients the re-elevation was not clinically relevant. However, as pointed out by Dr. Kamel and colleagues [<xref ref-type="bibr" rid="CR1">1</xref>], there are certain clinical situations in which a re-occurrence of the anticoagulant effect of dabigatran might be harmful. Consequently, a second dose of idarucizumab was allowed in the RE-VERSE AD clinical trial; the respective data will be available in the final publication when the trial is complete. Consideration of an additional dose is also proposed in the idarucizumab label. The criteria for the additional dose focus on both the clinical condition of the patient as well as the coagulation status:<list list-type="bullet"><list-item><p>recurrence of clinically relevant bleeding together with prolonged clotting times; or</p></list-item><list-item><p>patients require a second emergency surgery/urgent procedure and have prolonged clotting times [<xref ref-type="bibr" rid="CR3">3</xref>].</p></list-item></list>
</p><p>Dr. Kamel and colleagues further expressed interest in the non-renal contribution to idarucizumab elimination [<xref ref-type="bibr" rid="CR1">1</xref>]. As this involves unspecific catabolism in the body followed by recycling of amino acids, it is not feasible to conduct appropriate mechanistic studies to address this question clinically. Based on our data in healthy volunteers [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>], we feel confident that in healthy subjects, renal clearance is the major pathway resulting in rapid elimination of the drug. However, there is a dependency of idarucizumab exposure on renal function, and under conditions of more severe renal damage non-renal elimination pathways may have increased relevance. We are currently analyzing our data on renal elimination and intend to publish the results.</p><p>Finally, the value for creatinine clearance (CL<sub>CR</sub>) of volunteers with moderate renal impairment presented in our publication is correct. Volunteers with renal insufficiency were enrolled into the study based on their CL<sub>CR</sub> value at the screening visit. The value presented in the table refers to the measurement at baseline, i.e., shortly before idarucizumab administration. Some of the levels measured at baseline were higher in the same individuals than those measured at screening, explaining the discrepancy.</p></body><back><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar1"><title>Conflicts of interest</title><p>Stephan Glund, Joanne van Ryn, and Joachim Stangier are employees of Boehringer Ingelheim Pharma GmbH &#x00026; Co. KG. Paul Reilly is an employee of Boehringer Ingelheim Pharmaceuticals, Inc.</p></sec><sec id="FPar2"><title>Funding</title><p>None received.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Kamel KS, Chin PK, Doogue MP, Barclay ML. Comment on: &#x0201c;Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study&#x0201d;. Clinic Pharmacokinet. 2017. doi10.1007/s40262-016-0481-5.</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollack</surname><given-names>CV</given-names><suffix>Jr</suffix></name><name><surname>Reilly</surname><given-names>PA</given-names></name><name><surname>Eikelboom</surname><given-names>J</given-names></name><name><surname>Glund</surname><given-names>S</given-names></name><name><surname>Verhamme</surname><given-names>P</given-names></name><name><surname>Bernstein</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Idarucizumab for dabigatran reversal</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><fpage>511</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1502000</pub-id><pub-id pub-id-type="pmid">26095746</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">PRAXBIND prescribing information 2015. <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf</ext-link>. Accessed 3 Nov 2016.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glund</surname><given-names>S</given-names></name><name><surname>Moschetti</surname><given-names>V</given-names></name><name><surname>Norris</surname><given-names>S</given-names></name><name><surname>Stangier</surname><given-names>J</given-names></name><name><surname>Schmohl</surname><given-names>M</given-names></name><name><surname>van Ryn</surname><given-names>J</given-names></name><etal/></person-group><article-title>A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran</article-title><source>Thromb Haemost</source><year>2015</year><volume>113</volume><fpage>943</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1160/TH14-12-1080</pub-id><pub-id pub-id-type="pmid">25789661</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glund</surname><given-names>S</given-names></name><name><surname>Stangier</surname><given-names>J</given-names></name><name><surname>van Ryn</surname><given-names>J</given-names></name><name><surname>Schmohl</surname><given-names>M</given-names></name><name><surname>Moschetti</surname><given-names>V</given-names></name><name><surname>Haazen</surname><given-names>W</given-names></name><etal/></person-group><article-title>Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib Study</article-title><source>Clin Pharmacokinet. Epub</source><year>2016</year></element-citation></ref></ref-list></back></article>